rs544654228

Variant summary

Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2

The NM_002878.4(RAD51D):​c.493C>T​(p.Arg165Trp) variant causes a missense change. The variant allele was found at a frequency of 0.0000688 in 1,612,350 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R165Q) has been classified as Benign.

Frequency

Genomes: 𝑓 0.000053 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000071 ( 0 hom. )

Consequence

RAD51D
NM_002878.4 missense

Scores

9
9

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts P:1U:13

Conservation

PhyloP100: 4.82
Variant links:
Genes affected
RAD51D (HGNC:9823): (RAD51 paralog D) The protein encoded by this gene is a member of the RAD51 protein family. RAD51 family members are highly similar to bacterial RecA and Saccharomyces cerevisiae Rad51, which are known to be involved in the homologous recombination and repair of DNA. This protein forms a complex with several other members of the RAD51 family, including RAD51L1, RAD51L2, and XRCC2. The protein complex formed with this protein has been shown to catalyze homologous pairing between single- and double-stranded DNA, and is thought to play a role in the early stage of recombinational repair of DNA. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream ring finger and FYVE-like domain containing 1 (RFFL) gene. [provided by RefSeq, Jan 2011]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -4 ACMG points.

BS2
High AC in GnomAd4 at 8 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
RAD51DNM_002878.4 linkuse as main transcriptc.493C>T p.Arg165Trp missense_variant 6/10 ENST00000345365.11 NP_002869.3 O75771-1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
RAD51DENST00000345365.11 linkuse as main transcriptc.493C>T p.Arg165Trp missense_variant 6/101 NM_002878.4 ENSP00000338790.6 O75771-1
ENSG00000267618ENST00000593039.5 linkuse as main transcriptc.16C>T p.Arg6Trp missense_variant 2/72 ENSP00000466834.1 K7EN88

Frequencies

GnomAD3 genomes
AF:
0.0000526
AC:
8
AN:
152202
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000724
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000441
Gnomad OTH
AF:
0.000478
GnomAD3 exomes
AF:
0.0000404
AC:
10
AN:
247668
Hom.:
0
AF XY:
0.0000373
AC XY:
5
AN XY:
133870
show subpopulations
Gnomad AFR exome
AF:
0.0000641
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000545
Gnomad SAS exome
AF:
0.0000665
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000536
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000705
AC:
103
AN:
1460030
Hom.:
0
Cov.:
31
AF XY:
0.0000730
AC XY:
53
AN XY:
726106
show subpopulations
Gnomad4 AFR exome
AF:
0.000120
Gnomad4 AMR exome
AF:
0.0000225
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.0000466
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000774
Gnomad4 OTH exome
AF:
0.000116
GnomAD4 genome
AF:
0.0000525
AC:
8
AN:
152320
Hom.:
0
Cov.:
32
AF XY:
0.0000537
AC XY:
4
AN XY:
74476
show subpopulations
Gnomad4 AFR
AF:
0.0000722
Gnomad4 AMR
AF:
0.0000654
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000441
Gnomad4 OTH
AF:
0.000473
Alfa
AF:
0.0000580
Hom.:
0
Bravo
AF:
0.0000793
TwinsUK
AF:
0.00
AC:
0
ALSPAC
AF:
0.000259
AC:
1
ExAC
AF:
0.0000741
AC:
9
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Uncertain:5
Uncertain significance, criteria provided, single submitterclinical testingGeneKor MSAAug 01, 2018- -
Uncertain significance, no assertion criteria providedclinical testingTrue Health DiagnosticsJan 05, 2018- -
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsOct 03, 2024The p.R165W variant (also known as c.493C>T), located in coding exon 6 of the RAD51D gene, results from a C to T substitution at nucleotide position 493. The arginine at codon 165 is replaced by tryptophan, an amino acid with dissimilar properties. This alteration was identified in an individual diagnosed with breast and/or ovarian cancer who previously tested negative for a known familial BRCA1/2 mutation (Dominguez-Valentin M et al. Hered Cancer Clin Pract 2018 Jan;16:4). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
Uncertain significance, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthDec 27, 2022This missense variant replaces arginine with tryptophan at codon 165 of the RAD51D protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer, together with a pathogenic truncation variant in the ATM gene (PMID: 29371908). This variant has been reported in an unaffected control individual in a breast and ovarian cancer case-control study (PMID: 21822267). This variant has been identified in 13/279074 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submittercurationSema4, Sema4Aug 13, 2021- -
not provided Uncertain:3
Uncertain significance, criteria provided, single submitterclinical testingGeneDxAug 11, 2024In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26261251, 31159747, 32579932, 29371908, 21822267, 21111057, 14704354, 34284872, 33471991, 36243179) -
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoAug 05, 2024The RAD51D c.493C>T (p.Arg165Trp) variant has been reported in the published literature in individuals with breast cancer and a personal and/or family history of breast and/or ovarian cancer (PMID: 29371908 (2018), 31159747 (2019), 33471991 (2021)), see also LOVD (http://databases.lovd.nl/shared/genes/RAD51D). It has also been observed in reportedly healthy individuals (PMIDs: 21822267 (2011), 26261251 (2015), 33471991 (2021)), see also LOVD (http://databases.lovd.nl/shared/genes/RAD51D), 36243179 (2022)). The frequency of this variant in the general population, 0.00012 (3/24306 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Uncertain significance, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenDec 01, 2021- -
not specified Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpJun 12, 2023Variant summary: RAD51D c.493C>T (p.Arg165Trp) results in a non-conservative amino acid change located in the DNA recombination and repair protein Rad51-like, C-terminal domain; DNA recombination and repair protein RecA-like, ATP-binding domain; AAA+ ATPase domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.6e-05 in 259332 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in RAD51D causing Hereditary Breast And Ovarian Cancer Syndrome (4.6e-05 vs 0.00013), allowing no conclusion about variant significance. c.493C>T has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome (Dominguez-Valentin_2018 and Krivokuca_2022). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. Co-occurrences with other pathogenic variant(s) have been reported (ATM c.9139C>T, p.Arg3047Ter), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 21822267, 26261251, 29371908, 34284872). Ten clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified as VUS (n=9) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Uncertain significance, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalFeb 06, 2024- -
Breast-ovarian cancer, familial, susceptibility to, 4 Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsFeb 26, 2024- -
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 31, 2024This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 165 of the RAD51D protein (p.Arg165Trp). This variant is present in population databases (rs544654228, gnomAD 0.01%). This missense change has been observed in individual(s) with RAD51D-related conditions (PMID: 31159747, 34284872). ClinVar contains an entry for this variant (Variation ID: 127891). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RAD51D protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Lynch syndrome 1 Pathogenic:1
Likely pathogenic, flagged submissionclinical testingClinical Cancer Genetics and Family Consultants, Athens Medical CenterJun 05, 2019This variant is denoted RAD51D c.493C>T at the DNA level, p.Arg165Trp. The arginine residue is weakly conserved and there is a moderate physicochemical difference between Arginine and Tryptophan. This variant has not been reported in the literature in individuals with RAD51D related disease. It has never been reported so far in Greek population. In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. We observed this variant in a woman with ovarian cancer at the age of 44 years and her brother with undifferentiated gastric cancer at the age of 43 years. Two other sisters are healthy carriers at the age of 53 and 50 years. There was also ovarian and prostate cancer in second degree family members, from the paternal side. The phenotype in this family was consistent with Lynch Syndrome type II. This inherited syndrome in the above family has apparently a causative relation with RAD51D mutation c.493C>T, which is classified as likely pathogenic. -
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingCHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern OntarioMar 13, 2023- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.12
BayesDel_addAF
Benign
-0.14
T
BayesDel_noAF
Benign
-0.25
CADD
Pathogenic
33
DANN
Benign
0.97
DEOGEN2
Benign
0.42
.;.;T;T;.;.;.;T
Eigen
Uncertain
0.53
Eigen_PC
Uncertain
0.55
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.91
D;D;.;D;D;D;D;D
M_CAP
Uncertain
0.10
D
MetaRNN
Uncertain
0.43
T;T;T;T;T;T;T;T
MetaSVM
Benign
-0.30
T
MutationAssessor
Benign
1.7
.;.;L;L;.;.;.;.
PROVEAN
Uncertain
-3.2
.;.;D;D;.;.;.;.
REVEL
Benign
0.29
Sift
Uncertain
0.0020
.;.;D;D;.;.;.;.
Sift4G
Uncertain
0.0020
D;D;D;D;D;D;D;.
Polyphen
0.96, 1.0
.;.;D;D;D;.;.;.
Vest4
0.28
MutPred
0.53
.;.;Loss of disorder (P = 0.0172);Loss of disorder (P = 0.0172);.;.;.;.;
MVP
0.90
MPC
0.37
ClinPred
0.46
T
GERP RS
5.0
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.61
gMVP
0.30

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs544654228; hg19: chr17-33433488; COSMIC: COSV105193567; COSMIC: COSV105193567; API